Abstract
Neuromyelitis optica is an immune-mediated disease characterized by a relapsing course, resulting in progressive disability. In children, given the long life expectancy, a disease-modifying treatment could be particularly desirable. Unfortunately, the currently available treatment strategies with this potential are scarce. Very limited data are available about the use of allogeneic hematopoietic stem cell transplantation (HSCT) for autoimmune neurological diseases. In this report, we present a pediatric case successfully treated with allogeneic HSCT from an HLA-haploidentical donor, after ex vivo TCR/CD19-depletion of the graft. To the best of our knowledge, this is the first case of a pediatric patient to benefit from such a treatment.
| Lingua originale | Inglese |
|---|---|
| pagine (da-a) | 2110-2113 |
| Numero di pagine | 4 |
| Rivista | Annals of Clinical and Translational Neurology |
| Volume | 6 |
| DOI | |
| Stato di pubblicazione | Pubblicato - 2019 |
OSS delle Nazioni Unite
Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile
-
SDG 3 Salute e benessere
Keywords
- neuromyelitis optica
- HSCT
Fingerprint
Entra nei temi di ricerca di 'T-cell depleted HLA-haploidentical HSCT in a child with neuromyelitis optica'. Insieme formano una fingerprint unica.Cita questo
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver